Manav Malhotra, Richa Dhingra, Tina Sharma, Aakash Deep, Balasubramanian Narasimhan, Priyanka Phogat and Prabodh Chander Sharma Pages 915 - 920 ( 6 )
Cabazitaxel has recently been approved by FDA for the treatment of docetaxel resistant hormone-refractory prostate cancer. It has been developed by Sanofi-Aventis under the trade name of Jevtana. It is given in combination with prednisone/prednisolone and has passed the clinical trial over well-known drug mitoxantrone. This drug is a microtubule depolymerization inhibitor, which can penetrate blood brain barrier (BBB). The FDA granted fast track designation to this drug in November 2009 and thereafter, new drug application submission was done in March 2010. Priority review to this drug was granted in April 2010 and finally in July 2010 it was approved by FDA. It is available in the form of injection in the dose of 60 mg/1.5 mL, which should be diluted prior to its use by the diluents supplied along with the injection. It is a second-line drug and has proven to be effective in patients experiencing docetaxel based treatment failure.
Prostate cancer, Jevtana, Sanofi-aventis, Taxanes, Cabazitaxel, XRP-6258
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak-124001, Haryana, India.